Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer.

O'Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, Harland S, Robbins A, Halbert G, Nutley B, Jarman M. · 2004

Read Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. by O'Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, Harland S, Robbins A, Halbert G, Nutley B, Jarman M. (2004) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2409523.txt.

Introduction

O'Donnell and colleagues gave the first human tests of a hormone-blocking drug for prostate cancer in 2004. The drug, abiraterone acetate, blocks an enzyme that helps the body make testosterone, the male hormone that fuels prostate cancer. It was tested in three small dose-rising studies in men with and without prior castration treatment.

A single 500 milligram dose pushed testosterone below 0.14 nanomoles per litre in four of six castrate men, near the limit of detection. In men with working testes, 800 milligrams daily hit the target in all three patients at first. But rising luteinising hormone, the brain's counter-signal, broke the block within three days in two of them. By day 11 every patient on repeated dosing failed a standard adrenal stress test, though resting cortisol stayed normal. The authors proposed pairing the drug with steroid replacement.

Catalog record

CREATORO'Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, Harland S, Robbins A, Halbert G, Nutley B, Jarman M.
YEAR2004
COLLECTIONPAPERS
FORMATTXT
FILE SIZE39 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2409523

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer By A O'Donnell, I Judson, M Dowsett, F Raynaud, D Dearnaley, M Mason, S Harland, A Robbins, G Halbert, B Nutley, M Jarman Published in: British Journal of Cancer DOI: 10.1038/sj.bjc.6601879 ABSTRACT Abstract A series of three dose escalating studies were conducted to investigate the ability of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate, to cause maximum suppression of testosterone synthesis when delivered to castrate and noncastrate males with prostate cancer. Study A was a single dose study in castrate males. Study B was a single dose study in noncastrate males and study C was a multiple dose study in noncastrate males. The drug was given orally in a once-daily dose and blood samples taken to assess pharmacokinetic (PK) parameters and hormone levels in all patients. The study drug was well tolerated with some variability in PKs. Suppression of testosterone levels to <0.14 nmol l−1 was seen in four out of six castrate males treated with a single dose of 500 mg. At 800 mg given days 1–12 in noncastrate males, target suppression was achieved in three out of three patients, but a two- to three-fold increase of Luteinising Hormone (LH) levels in two out of three patients overcame suppression within 3 days. All patients in the multiple dose study developed an abnormal response to a short Synacthen test by day 11, although baseline cortisol levels remained normal. This is the first report of the use of a specific 17α-hydroxylase/17,20-lyase inhibitor in humans. Repeated treatment of men with intact gonadal function with abiraterone acetate at a dose of 800 mg can successfully suppress testosterone levels to the castrate range. However, this level of suppression may not be sustained in all patients due to compensatory hypersecretion of LH. The enhanced testosterone suppression achieved in castrate men merits further clinical study as a second-line hormonal treatment for prostate cancer. Adrenocortical suppression may necessitate concomitant administration of replacement glucocorticoid. Keywords: prostate cancer, hormonal therapy, pharmacokinetics, clinical study Prostate cancer continues to present an enormous challenge in the UK, where it is the second most common cause of cancer death in men, causing over 9000 deaths per year (Cancer Research UK, 2002). The beneficial effect of androgen ablation on metastatic prostate cancer was realised in the 1940s, when Huggins and Hodges observed an antitumour response, as measured by a reduction in serum acid phosphatase, in patients treated by surgical or medical castration (Denmeade and Isaacs, 2002). In general, androgen deprivation will give a response of varying duration in 80–90% of men with advanced disease (Denis and Murphy, 1993). Although the multistep pathway of androgen production resulting in testosterone (Figure 1) is present only in its entirety within the testes, the adrenal gland is also capable of releasing DHEA and androstenedione. Enzymes for the subsequent conversion of DHEA and androstenedione to testosterone are present in a variety of peripheral tissues as well as the prostate (Griffin and Wilson, 1998). [Figure: Steroid synthesis pathway. DHEA=dehydroepiandrosterone; 5αred=5αreductase; DHT=dihydrotestosterone.] Studies have shown that these extratesticular sources of testosterone represent an important alternative source of androgen stimulation in a significant proportion of patients with prostate cancer. As much as 10% of baseline circulating testosterone remains in castrated men, due to peripheral conversion of adrenal steroids to testosterone (Hellerstedt and Pienta, 2002). First-line treatment of prostate cancer by androgen deprivation is generally achieved by medical or surgical testicular castration. This leaves the testosterone derived from adrenal sources intact. It is recognised that the development of androgen-independent prostate cancer is caused, in part, by changes in androgen receptor regulation, activation of the androgen receptor being mitogenic in this malignancy. The sensitivity of the androgen receptor is increased by the overexpression of two nuclear coactivators: transcriptional intermediary factor 2 and steroid receptor coactivator 1. Transactivation of the androgen receptor is thus enhanced at lower concentrations of testosterone (Gregory et al, 2001a, 2001b). Furthermore, amplification of the number of androgen receptors can be shown in hormone refractory tumours, when compared to both benign prostatic hyperplasia and primary prostatic malignancy, using both reverse transcription PCR and fluorescence in situ hybridisation (Bubendorf et al, 1999; Linja et al, 2001). The imidazole derivative ketoconazole and the aromatase inhibitor aminoglutethimide have been evaluated as possible agents with which to achieve decreased production of adrenal steroids. Ketoconazole is relatively unselective, inhibiting both cholesterol side chain cleavage and 11β-hydroxylation (Loose et al, 1983). A direct antitumour effect of ketoconazole in vitro has also been demonstrated (Eichenberger and Trachtenberg, 1988). The action of aminoglutethimide is primarily to block the formation of pregnenolone from cholesterol but it is also recognised to inhibit 11β-hydroxylase and peripheral aromatase (Schwimmer and Parker, 1996). In clinical trials, both agents have shown some activity as second-line agents (measured by clinical benefit as well as reduction in PSA), supporting the concept of a more selective inhibitor of the 17α-hydroxylase/C17,20-lyase enzyme (Oh, 2002). The novel 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (Figure 2) was developed as a mechanism-based steroidal inhibitor following observations that nonsteroidal 3-pyridyl esters had improved selectivity for inhibition (Rowlands et al, 1995). Abiraterone acetate is the 3-acetate and a prodrug form of CB7598 (17-(3-pyridyl)androsta-5,16-dien-3β-ol, abiraterone), a potent inhibitor of the enzyme with a Kiapp of 0.5 nM (Barrie et al, 1997; Potter et al, 1995). [Figure: Abiraterone structure. R=H: abiraterone (CB7598); R=Ac: abiraterone acetate (CB7630).] Using a rodent model, following intraperitoneal administration, abiraterone acetate showed rapid deacetylation. Levels of deacetylated drug reached >1 μM at 6 h, with persistence of relatively high levels of compound (approximately 0.3 μM) for at least 24 h. Although this finding may be indicative of depot characteristics of the mode of administration used, it may also indicate a degree of enterohepatic recirculation that could prove favourable in the clinical setting, providing sustained target enzyme inhibition. In these preclinical studies, there was correlative evidence of inhibition of 17α hydroxylation as shown, for example, by the reduced weight of the ventral prostate (Barrie et al, 1994; Dowsett et al, 1988). Here, we describe a series of three phase one trials in which abiraterone acetate was tested in humans for the first time. This is the first report of the effects of a specific 17α-hydroxylase/C17,20-lyase inhibitor in humans. The studies were conducted to determine the dose of abiraterone acetate that will result in maximum suppression of testosterone and to obtain safety, pharmacokinetic (PK) and endocrine data, the latter to determine the specificity of inhibition. All three studies involved patients with advanced, that is, unresectable, prostate cancer. METHODS Patients were recruited to one of the following three studies that were conducted in sequence. The study protocols were approved by the Research Ethics Committee of all participating institutions, and all patients gave written informed consent prior to inclusion. All three studies were conducted under the auspices of the Cancer Research UK Phase I/II Committee. Study A This was a single dose study in males with castrate levels of testosterone (testosterone ⩽2 nmol l−1) following orchidectomy or Gonadotrophin-Releasing Hormone agonist (GnRHa) therapy, to determine the dose of abiraterone acetate that was sufficient to cause suppression of testosterone synthesis to undetectable levels (<0.14 nmol l−1). Significant suppression was defined as either testosterone <0.14 nmol l−1 in individual

Read the complete text